Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debio 4126 controlled release - Debiopharm

Next Previous
Drug Profile

Debio 4126 controlled release - Debiopharm

Alternative Names: Debio-4126

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Debiopharm
  • Class Antineoplastics; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acromegaly
  • No development reported Cancer; Neuroendocrine tumours

Most Recent Events

  • 08 Dec 2025 Debio 4126 is still in phase I trials for Acromegaly (Combination therapy) in, Spain, Poland, Italy, Israel, Germany, France, United Kingdom and Denmark (IM, injection) (NCT05364944)
  • 29 Sep 2025 Phase-III clinical trials in Acromegaly (Treatment-experienced) in Denmark, Lithuania, Italy, Israel, Hungary, Germany, France (IM) (NCT06930625), Austria, Belgium, Estonia, Latvia, Romania, Serbia, Slovakia, Poland, Spain (IM) (NCT06930625)
  • 28 Aug 2025 No recent reports of development identified for preclinical development in Cancer in Switzerland (Controlled release)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top